Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.71 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30118936 | 1.00 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2KMT2ACNR2 | |
| SCHEMBL7617859 | 0.88 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2KMT2ACNR2 | |
| SCHEMBL30048914 | 0.88 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2KMT2ACNR2 | |
| SCHEMBL30118960 | 0.84 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL22426339 | 0.84 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL22406337 | 0.84 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2KMT2ACNR2 | |
| SCHEMBL30118904 | 0.84 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2KMT2ACNR2 | |
| SCHEMBL5624004 | 0.82 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL22406333 | 0.82 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL22406356 | 0.82 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3938364-B1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ALTERITY THERAPEUTICS LTD (AU) | 2023-08-23 | — | — | EP | disclosed |
| EP-3938364-B1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ALTERITY THERAPEUTICS LTD (AU) | 2023-08-23 | — | — | EP | disclosed |
| EP-4168408-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2023-04-26 | — | — | EP | disclosed |
| CN-110563641-B | Ortho-halogenated phenyl pyridine ketone compound and preparation method thereof | 三峡大学 | 2023-03-24 | — | — | CN | disclosed |
| EP-3938364-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2022-01-19 | — | — | EP | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
| EP-3233799-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20190345105-A9 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190023656-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| EP-3233799-A1 | DOPAMINE D2 RECEPTOR LIGANDS | The Broad Institute Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016100823-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| CN-1023404-C | Process for producing benzopyran derivative | HOFFMANN LA ROCHE (CH) | 1994-01-05 | — | — | CN | disclosed |
| EP-0298452-B1 | 2H-1-BENZOPYRANE DERIVATIVES SUBSTITUTED IN POSITION 4 BY ARYL OR N-HETEROARYL | F. HOFFMANN-LA ROCHE AG (CH) | 1993-06-30 | — | — | EP | disclosed |
| US-5118694-A | Hypotensive agents; treatment for cardiovascular and muscular disorders | HOFFMANN-LA ROCHE INC. (US) | 1992-06-02 | — | — | US | disclosed |
| US-4971982-A | HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS, SMOOTH MUSCLE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1990-11-20 | — | — | US | disclosed |
| CN-1030582-A | 1-benzopyran derivatives | HOFFMANN LA ROCHE (CH) | 1989-01-25 | — | — | CN | disclosed |
| EP-0298452-A2 | 2H-1-benzopyrane derivatives substituted in position 4 by aryl or N-heteroaryl | F. HOFFMANN-LA ROCHE AG (CH) | 1989-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345105-A9 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | RAB9A 906/4885NPC1 2458/4885SMN1; SMN2 1443/4885 |
| US-11155547-B1 | Compounds for and methods of treating diseases | HTT, SNCA, PARK7 | RAB9A 1452/4885NPC1 277/4885SMN1; SMN2 10/4885 |
| US-20190023656-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | RAB9A 906/4885NPC1 2458/4885SMN1; SMN2 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.